Scinai Immunotherapeutics Ltd. (SCNI)
Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI ) Q2 2024 Results Conference Call August 20, 2024 11:00 AM ET Company Participants Liat Halpert - Head of Business Development Amir Reichman - CEO Liat Halpert Good morning, everyone.
Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 56% Today?
Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is taking off on Monday after the development stage biopharmaceutical company announced results from an early study. Scinai Immunotherapeutics revealed results from an in-vivo preclinical study of anti IL-17A/F VHH antibody fragment NanoAb.
Why Is Scinai Immunotherapeutics (SCNI) Stock Up 88% Today?
Scinai Immunotherapeutics (NASDAQ: SCNI ) stock is rocketing higher on Monday alongside heavy pre-market trading of the development-stage biopharmaceutical company's shares this morning. This has more than 7 million shares of SCNI stock changing hands as of this writing.
